Study Design & Arms

Comparison of Ribociclib + Fulvestrant vs Placebo + Fulvestrant in HR+/HER2- advanced breast cancer.

Time to Deterioration (TTD)

Comparison of months to 10% deterioration across key QOL metrics. Higher is better.

Baseline Global Health Status

Baseline scores (Mean ± SD) were well balanced between arms.

Hazard Ratios (Time to Deterioration)

HR < 1 favors Ribociclib. Error bars represent 95% CI.

Absolute Difference in TTD (Months)

Ribociclib Arm minus Placebo Arm. Positive values indicate longer time to deterioration.

Sample Size Distribution

2:1 Randomization Ratio.

Appendix: Raw Data & Provenance